BRICS Transcatheter Heart Valves Market (2022-2033)

The BRIC transcatheter heart valves market size is expected to reach US$ 1,611.6 million by 2033 from US$ 624.6 million in 2024. The market is estimated to record a CAGR of 11.1% from 2025 to 2033.

Executive Summary and BRICS Transcatheter Heart Valves Market Analysis:

The BRIC transcatheter heart valves market reflects a diverse landscape shaped by varying levels of healthcare infrastructure, patient demographics, and adoption of advanced cardiac technologies. Among Brazil, Russia, India, and China, the latter has emerged as the dominant force, driven by its vast patient population, strong government commitment to healthcare modernization, and rapid expansion of tertiary care facilities. Rising incidences of valvular heart disease, particularly linked to aging populations and lifestyle changes, have created significant demand for minimally invasive interventions across the bloc.

Market expansion in BRIC is propelled by increasing collaborations with global medtech companies, growing awareness of advanced treatment options, and the establishment of specialized cardiac centers in major urban areas. China's leadership is reinforced by its participation in international clinical trials and its ability to scale adoption quickly across large metropolitan regions. However, challenges persist across the bloc. Brazil and India face disparities in access between urban and rural populations, Russia contends with regulatory complexities and limited reimbursement pathways, and China itself continues to grapple with high device costs and reliance on imported technologies. Despite these hurdles, the BRIC market outlook remains positive, with China setting the benchmark for innovation, adoption, and regional growth.

BRICS Transcatheter Heart Valves Market - Strategic Insights:

BRICS Transcatheter Heart Valves Market Segmentation Analysis:

Key segments that contributed to the derivation of the BRICS transcatheter heart valves market analysis are valve type, application, and end user.

• In terms of valve type, the transcatheter heart valves market is segmented into aortic valve, mitral valve, tricuspid valve, and pulmonary valve. The aortic valve segment dominated the market in 2024.
• By application, the transcatheter heart valves market is segmented into aortic valve diseases, mitral valve diseases, tricuspid valve diseases, and pulmonary valve diseases. The aortic valve disease segment dominated the market in 2024.
• Based on end user, the transcatheter heart valve market is segmented into hospitals, ambulatory surgical centers, and cardiac catheterization labs. The hospitals segment dominated the market in 2024.

BRICS Transcatheter Heart Valves Market Drivers and Opportunities:

Increasing valvular disease diagnosis

In the BRIC countries, valvular heart diseases are becoming a significant health concern. In India and China, aging populations combined with lifestyle changes such as high blood pressure and sedentary habits are contributing to more cases of aortic and mitral valve diseases. In Brazil and Russia, rheumatic heart disease remains a factor in younger populations, adding to the overall burden. Growing awareness and improved diagnostic capabilities, such as echocardiography and cardiac imaging centers in urban areas, are helping detect these conditions earlier and more accurately.

Access to traditional surgical treatment is often limited in many parts of the BRIC countries. Rural populations may face logistical challenges in reaching specialized heart centers, and older patients with comorbidities are often considered high-risk for open-heart surgery. Transcatheter heart valves provide a less invasive alternative that can be performed in select hospitals with catheterization labs, making them an attractive solution for both physicians and patients. As a result, adoption of these therapies is growing steadily in urban and semi-urban healthcare settings.

Government initiatives and public-private partnerships are also supporting the adoption of minimally invasive heart care. Several cardiac centers are focusing on training interventional cardiologists and expanding infrastructure for catheter-based procedures. Coupled with increasing patient awareness of treatment options, the rising prevalence of valvular heart disease across BRIC nations is driving demand for transcatheter heart valves as a safer, accessible, and effective therapy.

Mitral & tricuspid THV opportunity expansion

While aortic valve interventions have been the main focus historically, the BRIC region is observing a growing clinical interest in mitral and tricuspid valve therapies. Urban hospitals in China, India, and Brazil are beginning to adopt transcatheter solutions for these complex valves, supported by advanced imaging and experienced interventional teams. In Russia, centers in Moscow and Saint Petersburg are piloting procedures for high-risk patients, signaling emerging opportunities in structural heart disease management.

Many patients with mitral or tricuspid valve disorders are elderly or have other medical conditions that make conventional surgery risky. Transcatheter therapies offer a minimally invasive solution, reducing recovery time and procedural complications. In countries with dense populations and limited hospital capacity for open-heart procedures, this approach allows more patients to receive timely treatment. Physicians are confident in selecting appropriate candidates, which drives procedural uptake.

For device manufacturers, the expansion into mitral and tricuspid interventions represents a strategic growth opportunity. Collaborating with hospitals to provide training, procedure support, and clinical data can accelerate adoption. As awareness increases among clinicians and patients across BRIC countries, the mitral and tricuspid valve segment is expected to become a key growth area in the transcatheter heart valve market, complementing the established aortic valve business.

BRICS Transcatheter Heart Valves Market Size and Share Analysis:

The BRICS Transcatheter Heart Valves market demonstrates steady growth, with size and share analysis highlighting evolving trends and competitive dynamics among key players. The report further examines subsegments categorized within valve type, application, and end user, offering insights into their contribution to overall market performance.

By valve type, the aortic valve subsegment dominated the market in 2024. The aortic valve segment dominated due to the high prevalence of aortic stenosis, growing preference for minimally invasive transcatheter aortic valve replacement (TAVR), and technological advancements ensuring improved patient outcomes and procedural safety.

In terms of application, the aortic valve disease subsegment dominated the market in 2024. Aortic valve disease dominated the market as rising cases of calcific aortic stenosis and aging populations increased demand for transcatheter interventions, making it the most treated condition requiring advanced valve replacement solutions.

By end user, the hospitals subsegment dominated the market in 2024. Hospitals serve as primary centers for complex cardiovascular procedures, offering advanced infrastructure, skilled cardiologists, and comprehensive patient care, making them the leading setting for transcatheter heart valve adoption.

BRICS Transcatheter Heart Valves Market Report Highlights:

BRICS Transcatheter Heart Valves Market Report Coverage and Deliverables:

The "BRICS Transcatheter Heart Valves Market Size and Forecast (2022–2033)" report provides a detailed analysis of the market covering below areas:

• BRICS Transcatheter Heart Valves market size and forecast at regional and country levels for key market segments covered under the scope
• BRICS Transcatheter Heart Valves market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• BRICS Transcatheter Heart Valves market analysis covering key market trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the BRICS Transcatheter Heart Valves market
• Detailed company profiles, including SWOT analysis

BRICS Transcatheter Heart Valves Market Geographic Insights:

The geographical scope of the BRIC Transcatheter Heart Valves market report is divided into: Russia, Brazil, South Africa, India, China, Egypt, Indonesia, Saudi Arabia, and the UAE. China held the largest share in 2024.

China dominates the BRIC transcatheter heart valves market due to its unique combination of scale, investment, and innovation. Major cities such as Beijing, Shanghai, and Guangzhou have become centers of excellence for transcatheter valve interventions, supported by advanced hospital networks and strong government initiatives to modernize healthcare delivery.

The country's leadership is reinforced by its active involvement in global clinical trials, which accelerates the introduction of new valve technologies and positions China as a hub for innovation in minimally invasive cardiac care. China's growing middle class and expanding national health insurance coverage have improved patient access to advanced therapies, particularly in urban areas. The country is also investing heavily in training programs for interventional cardiologists, ensuring a growing pool of specialists capable of performing complex procedures. Nonetheless, challenges remain. Rural populations often lack access to specialized cardiac care, and the high cost of imported devices continues to limit affordability for certain patient groups. Despite these barriers, China's dominance in the BRIC market is clear, setting the pace for adoption and establishing itself as the primary driver of growth and innovation in transcatheter heart valve technologies across the bloc.

BRICS Transcatheter Heart Valves Market Research Report Guidance:

• The report includes qualitative and quantitative data in the BRIC Transcatheter Heart Valves market across valve type, application, end user, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the BRIC Transcatheter Heart Valves market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the BRIC Transcatheter Heart Valves market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the BRIC Transcatheter Heart Valves market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 10 cover BRIC Transcatheter Heart Valves market segments by valve type, application, end user, and geography across Russia, Brazil, South Africa, India, China, Egypt, Indonesia, Saudi Arabia, and the UAE. They cover the market revenue, forecast, and factors driving the market.
• Chapter 11 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 12 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 13 provides detailed profiles of the major companies operating in the BRIC Transcatheter Heart Valves market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 14, i.e., the appendix, is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

BRICS Transcatheter Heart Valves Market News and Key Development:

The BRIC Transcatheter Heart Valves market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the BRIC transcatheter heart valves market are:

• In November 2025, Meril Life Sciences announced that it presented one‑year outcomes from the pivotal LANDMARK randomized controlled trial of its Myval THV series at PCR London Valves 2025, demonstrating that the indigenous Indian transcatheter heart valve performed comparably to leading global THV platforms and underscoring India's growing role in structural heart innovation.
• In September 2025, Medtronic plc announced that its Evolut FX+ transcatheter aortic valve replacement (TAVR) system was launched in India following regulatory approval by the Central Drugs Standard Control Organization, giving the world's most populous country access to the company's latest TAVR technology for treating severe aortic stenosis.

Key Sources Referred:

• The World Bank
• World Health Organization (WHO)
• Center for Disease Control and Prevention (CDC)
• European Society of Cardiology
• American College of Cardiology
• American Heart Association
• Asian Pacific Society of Interventional Cardiology
• Company Websites
• Company Annual Reports
• Company Investor Presentations